US00847G7051

Podrobnosti o dividendah

Razumevanje dividendnih izplačil od Agenus

Dividende od Agenus so del dobička podjetja, ki se izplača delničarjem. So ključen kazalec finančnega zdravja podjetja in privlačnosti za vlagatelje. Dividende vlagateljem nudijo stalni vir dohodka, poleg dobičkov, ki se lahko pridobijo s prodajo delnice po višji ceni od nakupne.

Primerjava iz leta v leto

Proučevanje dividendnih izplačil od Agenus čez leta lahko izpostavi donosnost in stabilnost podjetja. Konstantna ali naraščajoča dividendna izplačila lahko kažejo na finančno zdravo podjetje s predvidljivimi dobički, medtem ko lahko nihanje ali znižanja dividend nakazujejo na obstoječe finančne ali operativne izzive.

Vplivi na investicije

Izplačila dividend od Agenus so ključni dejavnik za vlagatelje, ki so usmerjeni na dohodek. Močno izplačilo dividend lahko poveča privlačnost delnice in zagotovi redni dohodek poleg morebitnih kapitalskih dobičkov. Lahko tudi pokaže zaupanje podjetja v svoje prihodnje dobičke in je tako pomemben dejavnik pri odločitvah o naložbah.

Interpretacija nihanj dividend

Spremembe v dividendah od Agenus lahko nastopijo zaradi sprememb v dobičkih podjetja, finančni politiki ali strategijah reinvestiranja. Povečanje dividend pogosto signalizira finančno stabilnost, medtem ko znižanje lahko nakazuje na potrebo po ohranjanju denarnih sredstev ali reinvestiranju dobičkov za spodbujanje rasti, pri čemer ima vsak scenarij različne posledice za vlagatelje.

Agenus Aktienanalyse

Kaj počne Agenus?

Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus je eno izmed najbolj priljubljenih podjetij na Eulerpool.com.

Pogosta vprašanja o delnici Agenus

Koliko dividende izplača Agenus?

V zadnjih 12 mesecih je Agenus izplačal dividendo v višini . To ustreza približni donosnosti dividend . V prihajajočih 12 mesecih bo Agenus predvidoma izplačal dividendo v višini 0 USD.

Kakšen je donos dividend od Agenus?

Trenutni donos od dividend za Agenus znaša .

Kdaj Agenus izplača dividend?

Agenus izplačuje četrtletno dividendo. Ta se izplačuje v mesecih .

Kako varna je dividenda od Agenus?

Agenus je v zadnjih 0 letih vsako leto izplačeval dividend.

Kakšna je dividenda od Agenus?

V naslednjih 12 mesecih se pričakuje dividende v višini 0 USD. To ustreza dividendnemu donosu 0 %.

V katerem sektorju se nahaja Agenus?

Agenus je razvrščen v sektor 'Zdravje'.

Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?

Da si prejel zadnjo dividendo Agenus z dne 21. 9. 2024 v višini 0 USD, si moral imeti delnico v depoju pred dnevom brez pravice do dividende (Ex-Tag) 21. 9. 2024.

Kdaj je Agenus izplačal zadnjo dividendo?

Zadnje izplačilo dividende je bilo 21. 9. 2024.

Kakšna je bila dividenda od Agenus v letu 2023?

V letu 2023 je Agenus 0 USD izplačal kot dividende.

V kateri valuti Agenus izplača dividendo?

Dividende od Agenus se izplačujejo v USD.

Agenus Dividenda 2024

Agenus Dividenda

Agenus Donosnost dividend

Simbol

ISIN

WKN

Koliko dividende izplača Agenus 2024?

Zgodovinske Agenus dividende

Je Agenus dividenda varna?